RetaMaps

Nicola Abate, MD

Nicola Abate, MD · 4002 GARTH RD STE 120 · Baytown, TX 77521

2.3· 6 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

Nicola Abate, MD, is a physician listed for weight-loss care in Baytown, Texas. Google shows a 2.3-star rating across 6 reviews dating back to 2024, with 3 posted in the past year. Reviewers most often mention the staff, and single reviews mention a caring approach and scheduling.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice website—
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 2.3
Google rating · 6 reviews
3
reviews in the past year (avg ★ 2.3)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-08-27. Read the reviews themselves on the practice's Google listing.

What patients say

This practice holds a ★2.3 Google rating across 6 reviews. 33% of the 6 reviews we analyzed are 5-star. reviewers most often mention staff & front desk (3), feeling listened to (1), scheduling & communication (1).

5★
2
4★
0
3★
0
2★
0
1★
4

Most recent Google reviews

Shelby J.★★★★★2026-08-27

This doctor is so rude and makes you feel like your sickness is your fault. Awful bedside manner. Will never go back.

Vickie F.★★★★★2026-05-03

Great Dr ! Really listens !

xolsens★★★★★2025-11-25

its weird that they have one person in the reviews admit they wrote one because they clicked a reviewer’s profile. clearly someone who works here doing that, which already is suspicious

Sugar B.★★★★★2025-09-18

Pam D (MeMe) i’m happy with the doctor and the front office staff have for the most part been nice. Something just told me to look at your profile and see if you’re ever happy …. six 1 star reviews and 5 star. Seems like you’re never happy 🤷🏼‍♀️ I give this office in A+. I originally came here just to Rate my doctor’s office but after I read your comment, I thought I’d leave a little extra.

Eva M.★★★★★2025-06-18

This doctor is a very rude doctor. Don’t care about his patience. His staff don’t answer the phone. He says it because they’re busy, but this is a place of business you make an appointment. You should be able to speak to someone within eight hours. You leave a message they do not call you back And then how do they expect for you to keep your appointments if they don’t even answer the phone I would never recommend this doctor or this establishment. They wasted my time and I don’t appreciate it.

Reviews and counts are from this practice's public Google Business listing and reflect their authors' opinions, not RetaMaps'. See all reviews on Google.

Clinicians

  • Nicola Abate, MD

Nearby providers in Baytown

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs